[1] |
Acharya NR, Tham VM, Esterberg E, et al. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study[J]. JAMA Ophthalmol,2013,131(11):1405-1412.
|
[2] |
Levy-Clarke GA, Nussenblatt RB, Smith JA. Management of chronic pediatric uveitis[J]. Curr Opin Ophthalmol,2005,16(5):281-288.
|
[3] |
Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis[J]. Ophthalmology,2009, 116(8):1544-1551,1551 e1541.
|
[4] |
Thorne JE, Woreta FA, Dunn JP, et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids[J]. Ophthalmology,2010,117(7):1436-1441.
|
[5] |
Buchman AL. Side effects of corticosteroid therapy[J]. J Clin Gastroenterol,2001,33(4):289-294.
|
[6] |
Kalinina Ayuso V, van de Winkel EL, Rothova A, et al. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis[J]. Am J Ophthalmol,2011,151(2):217-222.
|
[7] |
Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach[J]. Rheumatology (Oxford), 2013,52(5):825-831.
|
[8] |
Wentworth BA, Freitas-Neto CA, Foster CS. Management of pediatric uveitis[J]. F1000Prime Rep,2014,6:41.
|
[9] |
Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis[J]. Eye (Lond), 2009,23(5):1192-1198.
|
[10] |
Chang PY, Giuliari GP, Shaikh M, et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis[J]. Eye (Lond),2011,25(4):427-435.
|
[11] |
Gueudry J, LeHoang P, Bodaghi B. Anti-tumor necrosis factor-alpha agents in noninfectious uveitis[J]. Dev Ophthalmol, 2012,51(10):63-78.
|
[12] |
Mehta PJ, Alexander JL, Sen HN. Pediatric uveitis: new and future treatments[J]. Curr Opin Ophthalmol,2013,24(5):453-462.
|
[13] |
Imrie FR, Dick AD. Biologics in the treatment of uveitis[J]. Curr Opin Ophthalmol,2007,18(6):481-486.
|
[14] |
Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab [J]. Ophthalmology,2006,113(2):308-314.
|
[15] |
Sukumaran S, Marzan K, Shaham B, et al. High dose infliximab in the treatment of refractory uveitis: does dose matter?[J]. ISRN Rheumatol,2012:765380.
|
[16] |
Simonini G, Zannin ME, Caputo R, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis[J]. Rheumatology (Oxford),2008,47(10):1510-1514.
|
[17] |
Bou R, Iglesias E, Anton J. Treatment of uveitis associated with juvenile idiopathic arthritis[J]. Curr Rheumatol Rep,2014,16(8):437.
|
[18] |
Steenholdt C. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn′s disease[J]. Dan Med J,2013,60(4):B4616.
|
[19] |
Bravo-Ljubetic L, Peralta-Calvo J, Noval S, et al. Adalimumab therapy for refractory childhood uveitis[J]. J AAPOS,2013,17(5):456-459.
|
[20] |
Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry[J]. J Rheumatol,2013,40(1):74-79.
|
[21] |
Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab[J]. Arthritis Care Res (Hoboken),2011,63(4):612-618.
|
[22] |
Doycheva D, Zierhut M, Blumenstock G, et al. Immunomodulatory therapy with tumour necrosis factor alpha inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results[J]. Br J Ophthalmol,2014,98(4):523-528.
|
[23] |
Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey[J]. J Rheumatol,2007,34(5): 1146-1150.
|
[24] |
Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis[J]. Ann Rheum Dis,2007, 66(4):548-550.
|
[25] |
Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis[J]. Rheumatology (Oxford),2006,45(8):982-989.
|
[26] |
Dobner BC, Max R, Becker MD, et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis[J]. Br J Ophthalmol,2013,97(2):134-138.
|
[27] |
Sanchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, et al. Off-label uses of anti-TNF therapy in three frequent disorders: Behcet′s disease, sarcoidosis, and noninfectious uveitis[J]. Mediators Inflamm,2013,2013:286857.
|
[28] |
Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis[J]. Arthritis Care Res (Hoboken),2010, 62(6):821-825.
|